Yaara Oren

Yaara Oren

Auto-generated profile, based on publicly available information

Yaara Oren

Department of Cell Biology, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether the treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells and in EGFRi-treated patients presenting residual disease, we observed upregulation of GAS6, whereas ablation of GAS6's receptor, AXL, eradicated resistance. Reciprocally, AXL overexpression enhanced DTP survival and accelerated the emergence of T790M, an EGFR mutation typical to resistant cells. Mechanistically, AXL induces low-fidelity DNA polymerases and activates their organizer, RAD18, by promoting neddylation. Metabolomics uncovered another hypermutator, AXL-driven activation of MYC, and increased purine synthesis that is unbalanced by pyrimidines. Aligning anti-AXL combination treatments with the transition from DTPs to resistant cells cured patient-derived xenografts. Hence, similar to bacteria, tumors tolerate therapy by engaging pharmacologically targetable endogenous mutators. Significance: EGFR-mutant lung cancers treated with kinase inhibitors often evolve resistance due to secondary mutations. We report that in similarity to the bacterial SOS response stimulated by antibiotics, endogenous mutators are activated in drug-treated cells, and this heralds tolerance. Blocking the process prevented resistance in xenograft models, which offers new treatment strategies. This article is highlighted in the In This Issue feature, p. 2483

22 July 2022 in Molecular Systems Biology
Verified
Journal Article
Open access
YOYaara Oren
Yaara Oren
Similar to persister bacterial cells that survive antibiotic treatments, some cancer cells can evade drug treatments. This Commentary discusses the different classes of persister cells and their implications for developing more efficient cancer treatments.

10 May 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
YOYaara Oren
Yaara Oren

4 April 2023
Verified
Other
Open access
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

4 April 2023
Verified
Other
Open access
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer